InfuSystem vs OraSure Technologies
INFU and OSUR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INFU and OSUR compare
InfuSystem is the larger company, worth 1.2 times as much as OraSure Technologies ($293M against $250M).
InfuSystem grew revenue faster over the last twelve months (2.4% versus −7.5% for OraSure Technologies).
InfuSystem keeps more of each dollar of sales as profit, with a net margin of 6.5% compared with −41.7% at OraSure Technologies.
InfuSystem scores higher on the StockData Score (15 against 11 for OraSure Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INFU | OSUR |
|---|---|---|
| Size and price | ||
| Market cap | $293M | $250M |
| Share price | $14.72 | $3.62 |
| Change, 1 year | 41.1% | 46.6% |
| Change, 5 years | −17.6% | −63.1% |
| Beta (5Y) | 1.18 | 0.93 |
| Employees | 473 | 500 |
| StockData Score | ||
| Total score | 15 (better) | 11 |
| Valuation score | 3 | 3 |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 32.7× | – |
| P/S | 2.0× (better) | 2.1× |
| P/B | 4.6× | 0.8× (better) |
| EV/EBITDA | 11.2× | – |
| P/FCF | 11.8× | – |
| FCF yield | 8.4% (better) | −19.9% |
| Fair value | $15.28 | $5.86 |
| Margin of safety | 3.7% | 38.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 2.4% (better) | −7.5% |
| Revenue growth, 5Y average | 8.1% (better) | −7.7% |
| Net income growth (TTM) | 70.9% | – |
| EPS growth (TTM) | 73.1% | – |
| EPS growth, 5Y average | −17.3% | – |
| Profitability | ||
| Gross margin | 57.6% (better) | 43.1% |
| Operating margin | 9.8% (better) | −43.8% |
| Net margin | 6.5% (better) | −41.7% |
| FCF margin | 17.1% (better) | −42.7% |
| Return on equity | 15.8% (better) | −14.5% |
| Return on invested capital | 13.4% (better) | −26.4% |
| Financial health | ||
| Debt / equity | 0.31 (better) | 0.00 |
| Net debt / EBITDA | 0.39 | – |
| Interest coverage | 13.8× | – |
| Current ratio | 2.68 | 8.58 (better) |
| Altman Z-score | 5.75 (better) | 3.24 |
| Piotroski F-score | 8 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | 2.1% | 4.8% (better) |
| Shareholder yield | 2.1% | 4.8% (better) |
| Ownership | ||
| Held by institutions | 79.1% | 80.9% |
| Held by insiders | 12.2% | 17.6% |
| Insider net buying, 12 months | $150K | $546K (better) |
| Short interest, % of float | 3.9% | 4.6% |
Go deeper
- INFU stock overview
- INFU income statement
- INFU valuation and score
- OSUR stock overview
- OSUR income statement
- OSUR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.